Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bipolar disorder
Biotech
Alvogen snags NRx's bipolar depression drug in $330M deal
Alvogen will only make the initial $10 million cash payment upon seeing positive data from a phase 2b/3 clinical trial of the candidate.
Nick Paul Taylor
Jun 7, 2023 6:30am
AbbVie doubles down on Gedeon Richter pact
Mar 11, 2022 9:35am
Alkermes sees swift turnaround for rejected schizophrenia med
Dec 29, 2020 8:18am
FDA panel clashes over Alkermes' schizophrenia med's risks
Oct 9, 2020 7:00pm
FDA flags opioid concerns ahead of Alkermes schizophrenia AdComm
Oct 7, 2020 5:01pm
Virtual FDA AdComm for Alkermes' ALKS 3831 adds new focus on DDI
Aug 21, 2020 8:25am